BioTech
-
The inside story of Enhertu’s pan-tumor approval
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to…
Read More » -
Arvinas, Vertex, Leqembi, and more
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Medicare estimates $3.5 billion cost on Alzheimer’s drug Leqembi
Medicare for the first time has estimated that a new Alzheimer’s treatment could cost the program billions of dollars by…
Read More » -
Vertex to buy Alpine Immune Sciences for $4.9 billion
Vertex Pharmaceuticals will buy Alpine Immune Sciences, a maker of protein-based medicines that harness the immune system, for $4.9 billion,…
Read More » -
The latest on Xtandi, Triesence, and AskBio
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
After disappointments, cancer vaccines gain momentum at AACR- STAT
SAN DIEGO — Cancer vaccines have traveled a potholed road over the last decade. But as researchers from different companies…
Read More » -
Pfizer, Medivation, Aera, and Azalea
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Biotech startups post strongest financing numbers in two years
The numbers are in, and biotech startups recently closed out their best fundraising quarter in two years, signaling that the…
Read More » -
Seaport debuts with $100M Series A, as psychiatric boom grows
The team behind Karuna Therapeutics, which was recently snapped up in a multibillion-dollar deal, on Tuesday rolled out another neuropsychiatric-focused…
Read More » -
Grail, Stealth, Alnylam and more
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More »